Yale University  


A-Z Index

Technology Transfer at Yale

The Yale University Office of Cooperative Research is helping to turn Yale research into commercial opportunity and catalyzing regional development. Find out more...

The Buzzword Is 'Collaboration': Device Innovation at Yale

John Martin

John Martin, co-director of the Yale-UCL Collaborative
Photo Credit: John Curtis

The Yale Office of Cooperative Research held its first Innovation Workshop Series on Tues., April 22: "An Introduction to Device Innovation & Development at Yale," presented with the Yale School of Medicine. The workshop brought together leading thinkers on medical device technology and commercialization from government, industry and Yale faculty and staff. More...

Oasys Water, Using Yale Technology, Wins Water and Energy Awards

Clean Water

Oasys Water, a company that emerged from a Yale student invention, has been honored as both the Water Technology Company of the Year by Global Water Intelligence and as one of 10 New Energy Pioneers for 2014 by Bloomberg. Oasys' forward-osmosis technology, developed by Yale alum Rob McGinnis working with Menachem Elimelech, director of the Department of Chemical and Environmental Engineering at Yale, and patented by the Yale Office of Cooperative Research, relies on a highly efficient method for producing clean, drinkable water from contaminated fluids or saltwater. A draw solution of ammonium, carbon dioxide and other compounds pulls the salt and/or chemicals from the water and then is burned off at a much lower temperature, and for less than half the cost, of other methods of desalination. More...

Yale Women Innovators Honored

Clean Water

Three Yale women were honored at the March 27 Women of Innovation awards ceremony by the Connecticut Technology Council. Michelle Addington, Hines Professor of Sustainable Architectural Design at Yale School of Architecture was nominated for Academic Innovation and Leadership for her work advancing smart materials and environmental technologies. Julie Dorsey, Professor of Computer Science at Yale and cofounder of the startup Mental Canvas was nominated for Research Innovation and Leadership for advancing image synthesis, modeling material appearance and interactive illustration. Paula Kavathas, Professor of Laboratory Medicine, of Genetics, of Immunobiology and of Molecular, Cellular, and Developmental Biology at Yale was nominated for Academic Innovation and Leadership for advancing knowledge relevant to vaccine monitoring and immunotherapy. Congratulations to all the honorees!

Kolltan, Backed by Research at Yale Med School, Secures $60 Million in Financing

Joseph Schlessinger

Kolltan, a New Haven-based biotech company that is advancing a new generation of therapeutics in oncology and other diseases, announced the completion of a $60 million Series D financing round. Kolltan was cofounded by Dr. Joseph Schlessinger, chair of Pharmacology at Yale School of Medicine, one of the world’s leading cellular biologists and the inventor of several novel cancer treatments. Schlessinger’s research is focused on the cellular signals that switch on tumor growth and Kolltan is currently advancing a therapy called KTN3379 into Phase 2 clinical trials in cancer patients that is a potent inhibitor of this cellular signal.

Jon Soderstrom, Managing Director of OCR, Honored with Bayh-Dole Award

Jon Soderstrom

Jon Soderstrom, Managing Director of OCR, was honored with the 2014 Bayh-Dole Award during the 2014 Association of University Technology Managers (AUTM) annual meeting. More...

Yale Startup BioHaven Pharmaceutical Developing New Treatments for Anxiety and Depression


Yale researchers were among the first to identify ketamine – a drug best known for its use by club goers for its hallucinogenic effects—as a promising therapy for patients with treatment-resistant depression and anxiety. The finding was a major discovery that revealed a new pathway for treating these neuropsychiatric disorders. Rather than acting on the brain's levels of serotonin, norepinephrine and dopamine as other mood and anxiety drugs do, ketamine worked on regulating levels of a neurotransmitter called glutamate. "It's a completely different approach," says Gerard Sanacora, professor of psychiatry and director of the Yale Depression Research Program."It's an all-purpose approach that's physiologically-based across diagnostic categories." More...

Yale Partnership with GSK Aims to Reverse Memory Loss in Alzheimer's Disease

Paul Lombroso

Alzheimer's disease, which is marked by progressive memory loss, impaired cognitive function, loss of neurons and eventual death, impacts millions of people worldwide and is predicted to increase by many additional millions over the next decade. There are a few drugs to aid in memory loss and others used for behavioral symptoms like anxiety and depression, but no treatments have been found to halt or reverse the progress of the disease. Now, a protein discovered 25 years ago in the research lab of Paul Lombroso, MD, the Elizabeth Mears and House Jameson Professor in the Child Study Center at Yale, may offer new hope. More...

Yale Innovator


Joseph Schlessinger is one of the world’s leading cellular biologists and cancer-treatment inventors. More...

Top of page.